Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Fraction Absorbed of Ertugliflozin in Healthy Males
NCT02411929Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of ertugliflozin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration and Absolute Oral Bioavailability. Started Oct 2014; status: completed.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02411929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411929.